Clinical Trial of Low Intensity Shockwaves Therapy for Erectile Dysfunction Post-Radical Prostatectomy
NCT ID: NCT06152146
Last Updated: 2024-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2024-07-08
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low-intensity Shockwave Therapy for Post-radical Prostatectomy Erectile Dysfunction
NCT06219785
Early Shockwave Therapy for Post-RP ED
NCT03905057
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy
NCT00955929
Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer
NCT00244309
Focal Therapy for Prostate Cancer Using HIFU
NCT01194648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SWT group
Participants randomized to the treatment group will receive nine (9) shockwave sessions in total: one (1) shockwave session once per week for four (4) weeks, followed by one (1) shockwave session once per month (30±7 days) for the next five (5) months. 1,440 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura) for a total of 12,960 shocks. Participants will be in this group for up to 6 months.
Shockwave Therapy
Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
SHAM group
Participants randomized to the sham (control) group will have nine (9) sham therapy sessions in total: one (1) sham session once per week for four (4) weeks, followed by one (1) sham session once per month (30±7 days) for the next five (5) months. The shockwave machine will be set to deliver 1,440 shock treatments, but a barrier will be placed around the shockwave probe to ensure that no shockwaves are delivered. Participants will be in this group for up to 6 months.
SHAM shockwave therapy
Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shockwave Therapy
Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
SHAM shockwave therapy
Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be male
3. Be ≥ 40 and ≤ 75 years of age (inclusive).
4. Undergo radical prostatectomy for prostate cancer (nerve sparing or non-nerve sparing without neoadjuvant chemotherapy or radiation therapy.)
5. Be at least six weeks post radical prostatectomy.
6. Be in a stable sexual relationship for over 3 months prior to enrollment.
7. Have testosterone level of 300-1000 ng/dL within 1 month prior to enrollment.
8. Have an HbA1c level ≤ 7% within 3 months prior to enrollment.
9. Have undetectable PSA value at the time of enrollment
Exclusion Criteria
2. Be under judicial protection (prison or custody).
3. Be an adult under guardianship.
4. Refuse to sign the informed consent.
5. Have evidence of venous leak prior to surgery or use of PDE5i prior to surgery
6. Have past radiation therapy of the pelvic region or hormonal therapy with androgen deprivation within 12 months prior to enrollment.
7. Be recovering from any cancer within 12 months prior to enrollment (other than prostate cancer)
8. Have Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function (at the discretion of the investigator).
9. Have a Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications (at the discretion of the investigator).
10. Have an anatomical malformation of the penis, including Peyronie's disease.
11. Have testosterone level \<300 or \>1000 ng/dL within 1 month prior to enrollment.
12. Be using blood thinners with international normalized ratio (INR) to be \> 3.
13. Have received shockwave therapy for at least 6 months before enrollment.
14. Have detectable PSA value after the radical prostatectomy.
15. Require radiation therapy after radical prostatectomy.
16. Require hormonal therapy after radical prostatectomy.
40 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Russell Saltzman
Regulatory Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ranjith Ramasamy, MD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Desai Sethi Urology Institute - University of Miami, Miller School of Medicine
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20231090
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.